News

The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially harmful nonself molecules, and helps to control the development of immune cells that are key for this process, a new study shows. Findings suggest that activating DDX39B with small molecules…

Engaging in physical activity may improve the quality of life for people newly diagnosed with multiple sclerosis, a link that remained even after accounting for other factors such as fatigue and disability status, a study shows.

Pipeline Therapeutics will soon launch a Phase 1 clinical study to test PIPE-791, one of its candidate treatments for multiple sclerosis (MS), in healthy volunteers. The announcement follows a go-ahead from the U.S. Food and Drug Administration (FDA) for an investigational new drug (IND) application to initiate clinical…

Ocrevus (ocrelizumab) — given by infusion — may work better than certain oral treatments to prevent relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRMS) who transition from Tysabri (natalizumab), a new study found. Individuals who switched to Ocrevus also were more likely to stay…

The National Multiple Sclerosis Society (NMSS) has earned a shoutout from the digital fundraising platform DonorDrive for being recognized as one of the top 30 peer-to-peer fundraising programs in the U.S. by the Peer-to-Peer Professional Forum. MS Canada also made the list for the top…

Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (SPMS) who received treatment with Tiziana Life Science’s foralumab nasal spray. Microglia, resident immune cells in the brain, are believed to play a role in driving inflammation…

For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but certain forms of exercise may be better than others at improving specific measures of fitness, according to a review of multiple clinical trials. Results suggest that resistance training — pushing…

Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of multiple sclerosis (MS) — is driven in part by molecular mechanisms that are activated when microglia try to clear the corpses of dead myelin-making cells. That’s according to a new…

People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial. The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such…

Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability due to multiple sclerosis (MS) in a mouse model of the neurodegenerative disorder, a new study shows. Use of the novel strategy even cured some of the animals. “We…

Physical disability, not whether patients are depressed, when they’re diagnosed with multiple sclerosis significantly influences their future disability progression, according to a recent U.K. registry study. Although patients who were depressed at the time of their diagnosis were more likely to accumulate significant disability and require an aid to…

Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with distinct clinical features, new research shows. Given the variability of symptoms among people with MS, such groupings could help to improve individualized care for patients, according to Octave, a…

As part of last week’s World MS Day, a documentary about the life of Mathew Embry, a multiple sclerosis (MS) patient who’s been living symptom-free for more than 27 years, has premiered on national Canadian television. The critically acclaimed documentary, called “Living Proof,” premiered June 4 on The…

Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new data from an extension study show. Findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, in a poster titled “Assessment of Long-Term Safety…

The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis (MS) who have active disease, as defined by clinical or imaging features. The approval, which covers all member states in the European Union, as well as Iceland, Norway, and Liechtenstein,…

Being exposed to stress as children or adults makes it more likely that people with multiple sclerosis (MS) will experience more disability and/or a heavier burden from relapses, according to a new survey study of more than 700 people in the U.S. “MS is the leading cause of non-traumatic…

Frexalimab, an experimental anti-CD40L antibody therapy from Sanofi, significantly reduced the number of new brain lesions with active inflammation in people with relapsing forms of multiple sclerosis (MS), according to new Phase 2 clinical trial data. Sanofi believes its second-generation CD40L blocker will effectively control immune activity in…

A detailed examination of nerve tissue isolated from multiple sclerosis (MS) patients showed changes to the myelin sheath before the appearance of substantial inflammatory activity and lesions, a study reported. In MS patients, normal-appearing brain regions showed a less compact, detached, and disorganized myelin composition that may make…

In an effort to improve access to medical care for all people with multiple sclerosis (MS), the Consortium of Multiple Sclerosis Centers (CMSC) has announced new initiatives to address disparities and inequality in MS care. The consortium is incorporating a new statement on Diversity, Equity, and Inclusion (DEI)…

More treatment centers for people with autoimmune disorders such as multiple sclerosis (MS) are now available in Florida, as IVX Health expands its footprint across the state with the addition of two outpatient infusion and injection centers in the Fort Lauderdale area. With the new locations in Pembroke…

The National Multiple Sclerosis Society has awarded Clene Nanomedicine a grant to advance its treatment candidate CNM-Au8 for people with nonactive, progressive forms of multiple sclerosis (MS). The funding comes from the MS Society’s Fast Forward Program, which supports commercial organizations developing promising new MS therapies,…

The average rate of relapses for multiple sclerosis (MS) in the modern era is lower than it has been in decades past, according to a new analysis from the U.K. Scientists speculate the availability of new, more effective disease-modifying therapies may help explain why relapses appear to…

While fertility rates in women with multiple sclerosis (MS) have been increasing over time, they remain about two times lower than in the general population, a study in Italy has found. “There is a large gap in fertility between women with MS and the general population that needs to…

Monte Rosa Therapeutics has selected MRT-6160, its second candidate for development, for treating multiple sclerosis (MS) and several other autoimmune diseases. The therapy is now in early studies that would support an investigational new drug (IND) application, a formal request to U.S. regulatory authorities to start testing a…

Long-term treatment with Ocrevus (ocrelizumab) doesn’t change the diversity of T-cells — those needed to mount effective immune responses against foreign pathogens — in people with relapsing multiple sclerosis (MS) patients, a small study shows. Consistent with its mechanism of B-cell depletion, however, Ocrevus did reduce the molecular…

To mark World MS Day, which takes place annually on May 30, the International Progressive MS Alliance is introducing a research program to help drive early innovations in care programs for those with progressive forms of multiple sclerosis (MS). Specifically, the program seeks to identify solutions to…

People with relapsing-remitting multiple sclerosis (RRMS) who report better physical health are significantly more likely to see disability progression after three years, an observational study found. The findings suggest this patient-reported outcome measure may help predict long-term disability worsening in people with the condition. “Our findings…

Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in people with multiple sclerosis (MS) — among participants in two MS clinical trials, according to the results of a new analysis. “In this analysis, nabiximols was shown to significantly…

LAPIX Therapeutics has secured a new U.S. patent covering the use of its experimental oral therapy LPX-TI641 as a means to restore immune tolerance in people with autoimmune diseases such as multiple sclerosis (MS). Issued by the U.S. Patent and Trademark Office with the number 11,648,225, the patent…

A non-invasive treatment called acute intermittent hypoxia, or AIH, involving periods of oxygen deprivation, was found to ease signs and symptoms of progressive multiple sclerosis (MS) in a mouse model of the disease. Given during the peak of disease activity, AIH treatment — basically, periods of reduced oxygen exposure…